Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.41 |
| ▸ | FDPS | P14324 | 2/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10704293 | 0.85 | GGPS1 (0.44) | TSHRSMPD1FDPSGGPS1 | |
| SCHEMBL18400700 | 0.81 | DNM1 (0.65) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL24064593 | 0.81 | DNM1 (0.65) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL27637578 | 0.80 | DNM1 (0.93) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL28220393 | 0.80 | — | — | |
| Dodecylamine SCHEMBL27921132 | 0.80 | DNM1 (0.93) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL27921131 | 0.80 | — | — | |
| SCHEMBL27939655 | 0.80 | DNM1 (0.93) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Dodecylamine SCHEMBL6472452 | 0.79 | DNM1 (0.62) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Octadecylamine SCHEMBL5394797 | 0.79 | DNM1 (0.62) | DNM1TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000488-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20170253591-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253591-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | DNM1 3592/4885TSHR 1045/4885MEN1 3066/4885 |
| US-10000488-B2 | Heterocyclic compound | RORC, RORB, RORA | DNM1 3592/4885TSHR 1045/4885MEN1 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.